Compass Pathways PLC Sponsored ADR $CMPS Stock Acquired by Sumitomo Mitsui Trust Group Inc.

by · The Markets Daily

Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report) by 23.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 399,506 shares of the company’s stock after purchasing an additional 76,297 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.29% of Compass Pathways worth $4,970,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Compass Pathways during the third quarter valued at about $85,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Compass Pathways by 15.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company’s stock worth $317,000 after acquiring an additional 3,249 shares during the period. North Star Investment Management Corp. lifted its position in shares of Compass Pathways by 23.9% in the 3rd quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock worth $116,000 after acquiring an additional 1,800 shares during the period. Mount Vernon Associates Inc. MD grew its holdings in shares of Compass Pathways by 19.7% during the 3rd quarter. Mount Vernon Associates Inc. MD now owns 45,500 shares of the company’s stock worth $566,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Maxi Investments CY Ltd acquired a new stake in shares of Compass Pathways during the 3rd quarter worth approximately $1,070,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Trading Up 10.2%

CMPS stock traded up $0.80 during midday trading on Friday, hitting $8.61. 3,757,104 shares of the company’s stock were exchanged, compared to its average volume of 3,011,761. The company has a market cap of $1.19 billion, a PE ratio of -2.47 and a beta of 2.43. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The stock’s fifty day moving average price is $12.32 and its 200-day moving average price is $10.41. Compass Pathways PLC Sponsored ADR has a one year low of $4.88 and a one year high of $15.87.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. Research analysts predict that Compass Pathways PLC Sponsored ADR will post -0.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

CMPS has been the topic of several recent research reports. Jefferies Financial Group reiterated a “buy” rating on shares of Compass Pathways in a research report on Wednesday, September 9th. Oppenheimer restated an “outperform” rating and set a $20.00 price target on shares of Compass Pathways in a research note on Tuesday. BTIG Research reaffirmed a “buy” rating and set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday. Wall Street Zen lowered Compass Pathways from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Compass Pathways in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Compass Pathways currently has a consensus rating of “Moderate Buy” and an average price target of $23.14.

Get Our Latest Research Report on Compass Pathways

Compass Pathways Company Profile

(Free Report)

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

Further Reading

Want to see what other hedge funds are holding CMPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report).